Provenance Record

Well-structured News article with appropriate technical depth for a biomedical gene-editing trial. The What We Know / What We Don't Know / Analysis structure is well-executed. Word count (1060) is within the 400–1200 News range. The article correctly contextualizes Phase 1b limitations and does not overstate the findings.

7 of 8 sources verified from disk snapshots (source-0 through source-6). Source-7 (NEJM, https://www.nejm.org/doi/full/10.1056/NEJMoa2601283) returned HTTP 403 — no snapshot available; the publication claim is corroborated by all other sources. Source-0 (Lilly PR Newswire, source-0.html.gz): confirms headline stats (62% LDL-C, 88% PCSK9, 35 patients, 18-month durability, six dose cohorts, no treatment-related SAEs). Source-1 (BioSpace, source-1.html.gz): mirrors the PR; confirms Kathiresan quote verbatim and trial design details. Source-2 (BioPharma Dive, source-2.html.gz): confirms Phase 2 initiation by end of 2026 and the $1B Verve acquisition context. Source-3 (STAT News, source-3.html.gz): paywalled beyond lede; accessible text confirms VERVE-101 safety concern context and 'world's leading killer' attribution. Source-4 (STAT News pharmalot, source-4.html.gz): paywalled beyond lede; confirms 62% LDL reduction framing. Source-5 (Lilly acquisition PR, source-5.html.gz): confirms acquisition price ($10.50/share, ~$1.0B upfront, up to $3.00/share CVR, total ~$1.3B), date (June 17, 2025), Ruth Gimeno quote — but title discrepancy found (see factual_accuracy). Source-6 (Investing News Network, source-6.html.gz): syndication of Lilly press release; confirms all headline figures and durability claim.

One title misattribution found: the article states 'Ruth Gimeno, Lilly's group president for cardiometabolic health' but source-5 (Lilly acquisition press release, source-5.html.gz) identifies her as 'Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development.' This is a recoverable correction — the quote itself is accurate and the substance is unaffected. Additionally, the article states results were presented at 'the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece' — the EAS Congress and simultaneous NEJM publication are confirmed by multiple sources, but the ordinal '94th' and location 'Athens, Greece' do not appear in any of the 7 available snapshots. These are subordinate descriptive details in the Overview section (not the headline or summary) and are plausible for the 2026 EAS Congress, but they are unverifiable from captured snapshots. All other quantitative claims (62% LDL-C, 88% PCSK9, 35 patients, six dose cohorts, 9-month median follow-up, 15 patients at ≥1 year, 18-month durability, no treatment-related SAEs, FDA Fast Track designation, $1.0B acquisition price, $10.50/share, CVR up to $3.00/share) trace to cited sources.

Substantively strong submission. All core facts (efficacy figures, trial design, safety profile, acquisition price, regulatory status) are confirmed by cited sources. The article is APPROVE_WITH_CORRECTIONS: the Ruth Gimeno title error is a single correctable specific that does not affect the article's lead or headline, and the unverified EAS Congress specifics are subordinate description that can be noted. The article is otherwise publication-ready.